asti schreef op 11 november 2015 23:18:
Ozgur Ogut, de man van onder andere de uitgebreide vergelijkingen van jaks en het blog:
Abbvie to Galapagos: "It's not you, it's me"
September 27, 2015
Een gedeelte:
''- Galapagos has claimed filgotinib is the most JAK1 selective (over JAK2) of the investigational inhibitors, potentially conferring a safety advantage over predecessors like tofacitinib and baricitinib. This was often underlined by a focus on the anemia side effect profile, a talking point that I suggested was largely overblown. Galapagos claims that filgotinib is 3x more JAK1 selective than ABT-494 and by their own internal data, they claim filgotinib is also 3x more JAK1 selective than tofacitinib. This would place ABT-494 around the same JAK1 selectivity range as tofacitinib. In effect, Abbvie does not appear to be daunted by the proposition that JAK1 selectivity is a de facto advantage. In that regard, this selling point may not resonate as well with potential suitors.''
post vandaag op twitter:
twitter.com/Ogut_Ozgur/status/6645033...''ABT-494 safety in RA doesn’t look great past 6 mg BID. If dosing limited, then DAS scores may not impress.''
misschien dus toch die selectiviteit zoals glpg beweerde wat een voordeel op het gebied van veiligheid biedt...